Head-to-head · Cost-Efficiency Index
Found vs FuturHealth
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Found
Cost-first shoppers who also want behavior-change coaching bundled with the medication.
Visit FoundFuturHealth
Cost-first shoppers who want brand-name and compounded GLP-1s with registered-dietitian coaching.
Visit FuturHealthThe verdict
Found takes it, leading the Cost-Efficiency Index 88 to 55. The cheapest identical price on both molecules nationwide — unbeatable raw cost-per-month, capped only by a coaching subscription you can't fully unbundle. FuturHealth still earns a C — Cost-first shoppers who want brand-name and compounded GLP-1s with registered-dietitian coaching.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Found.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Found | FuturHealth |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 55/100 |
| Semaglutide / mo | $129/mo | $199/mo (compounded) |
| Tirzepatide / mo | $129/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,548 | $2,388 |
| Tirzepatide / yr (modeled) | $1,548 | — |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #7 | #299 |
Found
88/100Where the value is
- Lowest cost-per-month on the board — identical $129 on both molecules
- Nationwide
- Strong behavior-change program adds value
The tradeoffs
- Coaching subscription can't be unbundled, which reduces contract flexibility
- Compounded only
FuturHealth
55/100Where the value is
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
The tradeoffs
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.